The Retinal Disorder Drugs Market: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts​

Release Date: September 2018
Number of Pages: 238
Number of Tables and Figures: 46

Retinal disorders such as AMD (Age-Related Macular Degeneration) and diabetic eye disease can significantly impair vision by damaging the tissue layer at the back of the eye responsible for light detection. In severe cases, certain retinal disorders can even result in permanent blindness, making timely treatment critical.

Retinal disorders are typically treated with drugs, laser treatment or surgery. Largely dominated by anti-VEGF (Vascular Endothelial Growth Factor) therapies, drugs remain the preferred approach to treat most cases of retinal disorders. Retinal disorder drug sales are expected to account for more than $14 Billion by the end of 2018. The market is ripe for future growth with a number of product candidates in development – including long-acting VEGF inhibitors, dual inhibitors of Ang-2 (Angiopoietin-2)/VEGF, TKIs (Tyrosine Kinase Inhibitors), anti-integrin therapy, neuroprotective agents, Tie-2 activators, complement inhibitors, and gene and cell therapies
The “Retinal Disorder Drugs Market: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the retinal disorder drugs ecosystem including therapeutic areas, treatment options, key trends, market drivers, challenges, investment potential, leading therapies, delivery technologies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for retinal disorder drugs from 2018 through to 2030. The forecasts are segmented for 5 therapeutic categories, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report. 
For a Sample and Table of Contents please contact info@snsintel.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500
​
Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings: 
  • Retinal disorder drug sales are expected to account for more than $14 Billion by the end of 2018. The market is further expected to grow at a CAGR of approximately 13% over the next three year period, eventually accounting for more than $20 Billion in revenue by the end of 2021.
  • The R&D pipeline for retinal disorder drugs is robust, as drug developers continue to invest heavily in clinical development projects – with a primary focus on long-acting VEGF inhibition, dual inhibition of Ang-2 (Angiopoietin-2)/VEGF, TKIs (Tyrosine Kinase Inhibitors), anti-integrin therapy, neuroprotective agents, Tie-2 activation, complement inhibition, and gene and cell therapies.
  • The regulatory approval of next-generation anti-VEGF therapies, expected between 2019 and 2025, will pave the way for patient-friendly treatment regimens – with less frequent dosing than currently approved therapies for wet AMD.
  • The recent approval of Spark Therapeutics' Luxturna (Voretigene Neparvovec) for RPE65 mutation-associated retinal dystrophy, has opened the door to a new form of therapeutic intervention that uses genes to treat or prevent disease. Several gene therapies are presently in clinical development for rare conditions such as LHON (Leber Hereditary Optic Neuropathy), Stargardt disease and retinitis pigmentosa –  as well as AMD and diabetic retinopathy.

Topics Covered:
The report covers the following topics: 
  • Retinal disorder drugs ecosystem
  • Market drivers and barriers
  • Role of drugs in retinal disorders and key trends
  • Analysis of key drug classes and leading therapies
  • Drug development pipeline for retinal disorders
  • Advanced drug delivery technologies
  • Future roadmap and value chain
  • Profiles and strategies of over 80 leading ecosystem players, including retinal disorder drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2018 till 2030

Forecast Segmentation
Market forecasts are provided for each of the following submarkets and their subcategories:

Therapeutic Categories
  •  AMD (Age-Related Macular Degeneration)
    • Wet AMD
    • Dry AMD
  • Diabetic Eye Disease
  • Other Retinal Disorders

Regional Markets
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • North America
  • Latin & Central America

Country Markets
  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey
  • UK
  • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the retinal disorder drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2021, and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of complement inhibitors, neuroprotective agents, and other potential therapies for the treatment of dry AMD?
  • How will next-generation anti-VEGF therapies impact the wet AMD treatment landscape?
  • Who are the key market players, and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should drug developers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
4D Molecular Therapeutics
Acucela
Adverum Biotechnologies
Aerie Pharmaceuticals
Aerpio Therapeutics
Alimera Sciences
Allegro Ophthalmics
Allergan
Alteogen
Amgen
Ampio Pharmaceuticals
Apellis Pharmaceuticals
Astellas Pharma
Bausch + Lomb
Bayer
Benitec Biopharma
Bicycle Therapeutics
BioDiem
Bioeq IP
BioTime
BMS (Bristol-Myers Squibb)
Catalyst Biosciences
Cell Cure Neurosciences
Chengdu Kanghong Pharmaceuticals Group
Clearside Biomedical
Coherus BioSciences
Colby Pharmaceutical Company
Envisia Therapeutics
EyeGate Pharmaceuticals
EyePoint Pharmaceuticals
FCDI (FUJIFILM Cellular Dynamics, Inc.)
Formycon
ForSight VISION4
Galapagos
Gene Signal
Gensight Biologics
Glycadia Pharmaceuticals
Graybug Vision
GSK (GlaxoSmithKline)
Healios
Helvetic BioPharma
Icon Bioscience
Iconic Therapeutics
Intas Pharmaceuticals
Kala Pharmaceuticals
KalVista Pharmaceuticals
Kissei Pharmaceutical
Kodiak Sciences
Kubota Pharmaceutical Holdings
MacuCLEAR
Mimetogen Pharmaceuticals
Molecular Partners
MorphoSys
Mosaic Biosciences
NeuMedics
Neurotech Pharmaceuticals
Novartis
Novelion Therapeutics
NovelMed Therapeutics
OcuCure Therapeutics
Ocular Therapeutix
Ohr Pharmaceutical
ONL Therapeutics
Ophthotech Corporation
Opthea
Oxford BioMedica
Oxurion
PanOptica
Pfenex
Pfizer
pSivida Corporation
Quark Pharmaceuticals
Regeneron Pharmaceuticals
REGENXBIO
RetroSense Therapeutics
Roche Holding (F. Hoffmann-La Roche)
RXi Pharmaceuticals Corporation
Sanofi
Santen Pharmaceutical Company
SciFluor Life Sciences
Senju Pharmaceutical Company
Sesen Bio
Shire
Spark Therapeutics
STADA Arzneimittel
Stealth BioTherapeutics
Stemedica Cell Technologies
Sumitomo Dainippon Pharma
TRACON Pharmaceuticals
Tyrogenex
U.S. FDA (Food and Drug Administration)
Valeant Pharmaceuticals International
Vision Medicines
Xbrane Biopharma